Drug Database · Clinicians

Benzonatate

Brands (1) LobenzShow all

US brand (reference label): Benzonatate 100 mg; not a Philippine-registered brand.

Non-narcotic Antitussive US FDA class
Cough suppressant PH FDA category

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 5adfd324-b6d6-f624-e063-6294a90ab26e, version date September 7, 2026 (Benzonatate 100 mg · TIME CAP LABORATORIES, INC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS & USAGE Benzonatate capsules are indicated for the symptomatic relief of cough.
US FDA label
Full indications and usage US FDA label

INDICATIONS & USAGE Benzonatate capsules are indicated for the symptomatic relief of cough.

Contraindications

CONTRAINDICATIONS Hypersensitivity to benzonatate or related compounds.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE & ADMINISTRATION Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

PEDIATRIC USE Pediatric Use: Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

Dosage forms

Philippines

  • Softgel capsule: 100 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Benzonatate as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Benzonatate
Package insert
LobenzBenzonatate
100 mg Softgel CapsuleHDPE Bottle with PP Cap (Box of 1 bottle x 500 capsules with desiccant)
Rx
Lotus Pharmaceutical Co., Ltd. (Nantou Plant)Taiwan
Metro Drug, Inc.Trader: Lotus International Pte. Limited (Lotus SG)
DR-XY49438
Jul 1, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.

Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10.

Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE)

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Potential Adverse Reactions to benzonatate may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS: sedation; headache; dizziness; mental confusion; visual hallucinations. GI: constipation; nausea; GI upset. Dermatologic: pruritus; skin eruptions. Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

Pregnancy considerations

Pregnancy (US label) US FDA label

PREGNANCY Usage in Pregnancy: Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

NURSING MOTHERS Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate is administered to a nursing woman.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Benzonatate 100 mg · TIME CAP LABORATORIES, INC [US FDA-approved label, version 1, September 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5adfd324-b6d6-f624-e063-6294a90ab26e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .